Exhaled CO₂ as COVID-19 infection risk proxy for different indoor environments and activities

Abstract

CO₂ is co-exhaled with aerosols containing SARS-CoV-2 by COVID-19 infected people and can be used as a proxy of SARS-CoV-2 concentrations indoors. Indoor CO₂ measurements by low-cost sensors hold promise for mass monitoring of indoor aerosol transmission risk for COVID-19 and other respiratory diseases. We derive analytical expressions of CO₂-based risk proxies and apply them to various typical indoor environments. The relative infection risk in a given environment scales with excess CO₂ level, and thus keeping CO₂ as low as feasible in a space allows optimizing the protection provided by ventilation. We show that the CO₂ level corresponding to a given absolute infection risk varies by over 2 orders of magnitude for different environments and activities. Although large uncertainties, mainly from virus exhalation rates, are still associated with infection risk estimates, our study provides more specific and practical recommendations for low-cost CO₂-based indoor infection risk monitoring.

• Download figure
• Open in new tab

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

No external funding

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This is a modeling study. Data were computationally generated.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes